Actavis’s Bicalutamide, the generic version of AstraZeneca’s Casodex, is used as a treatment for prostate cancer and will be available in tablet form in 50mg doses in all three markets, as well as in 150mg doses in the UK.
Svend Andersen, executive vice president of Western Europe sales at Actavis, said: “We are pleased to be the first generic pharmaceutical company to bring this product to the market – creating value for patients at a lower price. Bicalutamide is an important product in Actavis’s portfolio.”